Representative Jefferson Shreve (R-Indiana) recently bought shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Johnson & Johnson stock on March 5th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $15,001 - $50,000 in shares of Harley-Davidson NYSE: HOG on 3/31/2025.
- Purchased $50,001 - $100,000 in shares of Block NYSE: XYZ on 3/31/2025.
- Sold $15,001 - $50,000 in shares of DuPont de Nemours NYSE: DD on 3/31/2025.
- Purchased $15,001 - $50,000 in shares of United Community Banks NASDAQ: UCB on 3/31/2025.
- Sold $15,001 - $50,000 in shares of IDEX NYSE: IEX on 3/31/2025.
- Purchased $15,001 - $50,000 in shares of HNI NYSE: HNI on 3/31/2025.
- Sold $50,001 - $100,000 in shares of ServiceNow NYSE: NOW on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Coinbase Global NASDAQ: COIN on 3/31/2025.
- Sold $15,001 - $50,000 in shares of Constellation Energy NASDAQ: CEG on 3/31/2025.
- Sold $50,001 - $100,000 in shares of Simon Property Group NYSE: SPG on 3/31/2025.
Johnson & Johnson Stock Performance
NYSE JNJ traded up $3.51 during trading on Friday, reaching $157.42. The company's stock had a trading volume of 10,972,370 shares, compared to its average volume of 7,953,112. The firm has a market cap of $379.37 billion, a price-to-earnings ratio of 23.67, a P/E/G ratio of 2.56 and a beta of 0.49. The business's fifty day moving average price is $159.47 and its 200-day moving average price is $155.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.30%. Johnson & Johnson's dividend payout ratio (DPR) is currently 74.59%.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of JNJ. Principal Financial Group Inc. increased its holdings in Johnson & Johnson by 10.5% in the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company's stock valued at $562,723,000 after buying an additional 329,473 shares during the last quarter. Neo Ivy Capital Management purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $242,000. Invst LLC raised its stake in Johnson & Johnson by 394.0% in the 3rd quarter. Invst LLC now owns 10,290 shares of the company's stock valued at $1,668,000 after purchasing an additional 8,207 shares during the last quarter. McIlrath & Eck LLC lifted its position in Johnson & Johnson by 10.7% during the third quarter. McIlrath & Eck LLC now owns 2,892 shares of the company's stock worth $469,000 after buying an additional 279 shares during the period. Finally, Passumpsic Savings Bank acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth $262,000. 69.55% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on JNJ. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Bank of America lowered their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Nine research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $171.72.
Get Our Latest Stock Analysis on JNJ
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
